Netherlands Radiotherapy Market Report 2022 to 2030

Netherlands Radiotherapy Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands Radiotherapy Market will reach a value of $xx Mn from $18 Mn in 2022, growing at a CAGR of xx% during 2022-30. The Radiotherapy Therapeutics Market in the Netherlands is dominated by a few domestic players such as Research Laboratories BV, Philips Healthcare, and Elekta BV. The radiotherapy market in the Netherlands is segmented into different types, technologies, procedures, applications, and end-users. The significant risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Netherlands Radiotherapy is increasing due to the rise in cancer cases in the country.

ID: IN10NLPH043 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Radiotherapy Market Analysis Summary

By 2030, it is anticipated that the Netherlands Radiotherapy Market will reach a value of $xx Mn from $18 Mn in 2022, growing at a CAGR of xx% during 2022-30.

The Netherlands is a high-income, developed constituent country located in Western Europe and with territories in the Caribbean. In the Netherlands, although 56,000 persons were diagnosed with cancer in 1989, this figure had climbed to 118,000 by 2019. Those in the Netherlands are more likely than people in practically every other European country to have cancer. Melanoma and colon cancer are more common in men and women in the Netherlands than in other European countries. According to data from the Dutch Cancer Registry and Statistics Netherlands (CBS), 117,631 persons were diagnosed with cancer in 2019. Skin cancer accounted for 22,600 of those diagnoses, with breast cancer accounting for nearly 17,000 and lung cancer accounting for 13,800.

The population-based Dutch cancer registry collects data on all cancer patients newly diagnosed in the Netherlands. The Dutch government is committed to the "smoke-free initiative." The Netherlands' government spent 11.1% of its GDP on healthcare in 2020.

Netherlands Radiotherapy Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The Netherlands is the only country that has regularly been rated in the top three in the European Health Consumer Index since 2005. By 2040, the Dutch government hopes that no one will start smoking. To attain this purpose, several tactics have been implemented. If palliative care specialists are necessary, 14 ESMO-designed integrated cancer and palliative care centres are available (with this number, the Netherlands ranks fourth in Europe). The Netherlands' improving infrastructure and living quality are a plus. Health insurance is mandatory in the Netherlands, which makes treatments more affordable. In the Netherlands, about 40% of radiation therapy centres are academic, with academic institutes treating 56% of all patients. These aspects could boost Netherlands Radiotherapy Market.

Market restrains.

The Dutch pension system is under strain as the population ages, as insurance is available to all citizens. There are 79 hospitals (in all, 109 locations), seven of which are university medical centres, one of which is a cancer centre, and the rest are large teaching hospitals. These factors may deter new entrants into the Netherlands Radiotherapy Market.

Competitive Landscape

Key Players

Elekta BV - a subsidiary of Elekta, a Swedish company that specializes in radiation therapy, radiosurgery, and brachytherapy equipment
Philips Healthcare - a Dutch multinational company that produces medical equipment, including radiation therapy equipment
MeVis Medical Solutions AG - a German company with a subsidiary in the Netherlands that produces medical imaging software, including for radiation therapy planning
Research Laboratories BV - a subsidiary of RaySearch Laboratories, a Swedish company that develops software for radiation therapy planning
Zuidnederlandse Kankercentrale (ZNKC) - a Dutch company that provides radiation therapy services and also develops radiation therapy equipment

Healthcare Policies and Reimbursement Scenarios

In the Netherlands, radiotherapy is regulated by the Dutch Health and Youth Care Inspectorate (IGJ), which is responsible for ensuring the quality and safety of healthcare services in the country. Radiotherapy is reimbursed by the government-funded health insurance scheme, the National Health Insurance Fund (Zorgverzekeringswet), which covers the majority of the costs of radiotherapy treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Radiotherapy Segmentation

By Type (Revenue, USD Billion):

External Beam Radiation Therapy
Linear Accelerators
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
?Tomotherapy
Proton Therapy
Cyclotron
?Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Radiation Therapy
?Others

?By Technology (Revenue, USD Billion):

External Beam Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Stereotactic Radiation Therapy (SRT)
3D Conformal Radiation Therapy (3D-CRT)
Particle Therapy
Internal Beam Radiotherapy
Brachytherapy
High-Dose Rate Brachytherapy
Low-Dose Rate Brachytherapy
Image-Guided Brachytherapy
Pulse-Dose Rate Brachytherapy
Systemic Radiation Therapy
Intravenous Radiotherapy
Oral Radiotherapy?

By Application (Revenue, USD Billion):

Breast Cancer
Cervical Cancer
Colon and rectum Cancers
Stomach Cancer
Lung Cancer
Prostate Cancer
Skin Cancer
Liver Cancer
Other types of cancer

By End User (Revenue, USD Billion):

Hospitals
Radiotherapy Centers & Ambulatory Surgery Centers
?Cancer Research Institutes

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.